Hologic, Inc. (NASDAQ:HOLX) Insider Sells $200,298.15 in Stock

Hologic, Inc. (NASDAQ:HOLX) insider Peter J. Valenti III sold 4,545 shares of Hologic stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $44.07, for a total transaction of $200,298.15. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

NASDAQ HOLX traded up $0.31 during trading on Friday, hitting $48.02. 2,093,057 shares of the company’s stock were exchanged, compared to its average volume of 1,749,319. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.02 and a current ratio of 1.45. The stock has a market capitalization of $12.75 billion, a P/E ratio of 21.53, a PEG ratio of 2.20 and a beta of 0.69. Hologic, Inc. has a fifty-two week low of $37.47 and a fifty-two week high of $49.78. The firm’s 50 day moving average price is $46.23.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, May 1st. The medical equipment provider reported $0.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.01. Hologic had a positive return on equity of 26.73% and a negative net margin of 0.32%. The firm had revenue of $818.40 million during the quarter, compared to the consensus estimate of $806.99 million. During the same quarter in the previous year, the firm earned $0.53 earnings per share. The business’s quarterly revenue was up 3.7% on a year-over-year basis. On average, equities analysts predict that Hologic, Inc. will post 2.42 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund increased its stake in shares of Hologic by 3,960.1% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 1,222,766 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 1,192,649 shares during the period. Horan Capital Advisors LLC. bought a new stake in Hologic in the first quarter valued at approximately $33,000. Lindbrook Capital LLC bought a new stake in Hologic in the fourth quarter valued at approximately $36,000. Essex Savings Bank bought a new stake in Hologic in the fourth quarter valued at approximately $37,000. Finally, First Interstate Bank bought a new stake in Hologic in the first quarter valued at approximately $40,000. 96.38% of the stock is owned by institutional investors.

HOLX has been the subject of a number of recent research reports. TheStreet raised shares of Hologic from a “c” rating to a “b” rating in a research report on Monday, March 4th. Needham & Company LLC reissued a “buy” rating and issued a $50.00 target price on shares of Hologic in a research report on Tuesday, April 2nd. Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $53.00 target price for the company in a research report on Tuesday, March 5th. BidaskClub cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 4th. Finally, BTIG Research reissued a “buy” rating and issued a $52.00 target price on shares of Hologic in a research report on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $45.02.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

See Also: How is a price target determined?

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.